The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P<0.0001, overall). The EUTOS Long-Term Survival score showed better differentiation of progression-free survival than the Sokal (<45 years), Euro and EUTOS scores in children and adolescents with chronic myeloid leukemia and should be considered in therapeutic algorithms.

Millot, F., Guilhot, J., Suttorp, M., Gunes, A., Sedlacek, P., De Bont, E., et al. (2017). Prognostic discrimination based on the EUTOS long-term survival score within the international registry for chronic myeloid leukemia in children and adolescents. HAEMATOLOGICA, 102(10), 1704-1708 [10.3324/haematol.2017.170035].

Prognostic discrimination based on the EUTOS long-term survival score within the international registry for chronic myeloid leukemia in children and adolescents

Biondi A.;
2017

Abstract

The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P<0.0001, overall). The EUTOS Long-Term Survival score showed better differentiation of progression-free survival than the Sokal (<45 years), Euro and EUTOS scores in children and adolescents with chronic myeloid leukemia and should be considered in therapeutic algorithms.
Articolo in rivista - Articolo scientifico
Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prognosis; Registries; Treatment Outcome
English
2017
102
10
1704
1708
none
Millot, F., Guilhot, J., Suttorp, M., Gunes, A., Sedlacek, P., De Bont, E., et al. (2017). Prognostic discrimination based on the EUTOS long-term survival score within the international registry for chronic myeloid leukemia in children and adolescents. HAEMATOLOGICA, 102(10), 1704-1708 [10.3324/haematol.2017.170035].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/239281
Citazioni
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 34
Social impact